

Peter Hayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2994540/publications.pdf>

Version: 2024-02-01

27
papers

742
citations

758635

12
h-index

713013

21
g-index

27
all docs

27
docs citations

27
times ranked

1188
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	3.7	188
2	Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV-1 Vaccine Candidates. <i>Journal of Infectious Diseases</i> , 2010, 201, 720-729.	1.9	74
3	Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention. <i>Annals of Internal Medicine</i> , 2016, 164, 313.	2.0	70
4	Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. <i>Vaccine Journal</i> , 2009, 16, 147-155.	3.2	57
5	Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. <i>PLoS ONE</i> , 2010, 5, e14330.	1.1	47
6	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. <i>PLoS ONE</i> , 2015, 10, e0134287.	1.1	39
7	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16061.	1.8	39
8	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. <i>Journal of Infectious Diseases</i> , 2017, 215, 95-104.	1.9	38
9	Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant Pol epitopes. <i>Vaccine</i> , 2016, 34, 1215-1224.	1.7	35
10	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. <i>PLoS ONE</i> , 2015, 10, e0125954.	1.1	31
11	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. <i>Journal of Immunological Methods</i> , 2014, 409, 161-173.	0.6	28
12	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. <i>Vaccine Journal</i> , 2013, 20, 397-408.	3.2	23
13	Humoral and cellular immune response induced by rVSV-G-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea. <i>Vaccine</i> , 2020, 38, 4877-4884.	1.7	14
14	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. <i>PLoS ONE</i> , 2014, 9, e90378.	1.1	13
15	The Safety and Immunogenicity of GTU-MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART. <i>Frontiers in Immunology</i> , 2019, 10, 2911.	2.2	11
16	Comprehensive epitope mapping using polyclonally expanded human CD8 T cells and a two-step ELISpot assay for testing large peptide libraries. <i>Journal of Immunological Methods</i> , 2021, 491, 112970.	0.6	8
17	Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India. <i>PLoS ONE</i> , 2020, 15, e0229461.	1.1	7
18	Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set. <i>PLoS ONE</i> , 2021, 16, e0260118.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. <i>Vaccines</i> , 2020, 8, 260.	2.1	5
20	Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials. <i>African Journal of Laboratory Medicine</i> , 2021, 10, 1056.	0.2	5
21	A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 634832.	2.2	4
22	Title is missing!. , 2020, 15, e0229461.		0
23	Title is missing!. , 2020, 15, e0229461.		0
24	Title is missing!. , 2020, 15, e0229461.		0
25	Title is missing!. , 2020, 15, e0229461.		0
26	Title is missing!. , 2020, 15, e0229461.		0
27	Title is missing!. , 2020, 15, e0229461.		0